PRMT5 and breast carcinoma: PRMT5 has been reported as a critical component of normal stem cell function (Chittka et al., 2012, Liu et al., 2015), hence one potential limitation of PRMT5-directed therapies for breast cancer is the suppression of normal mammary stem cell function.